{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:35:25Z","timestamp":1793968525153,"version":"4.8.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.breast.2024.103681","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T12:09:18Z","timestamp":1707480558000},"page":"103681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive\/HER2-negative advanced breast cancer: The randomized Tempo Breast study"],"prefix":"10.1016","volume":"74","author":[{"given":"Gilles","family":"Freyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Martinez-Ja\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo\u017cena","family":"Kukielka-Budny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Ulanska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serafin","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Bayo","family":"Calero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8950-8561","authenticated-orcid":false,"given":"Laura","family":"Cortesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Pint\u00e9r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark\u00e9ta","family":"Pal\u00e1cov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelli","family":"Cherciu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Petru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Ettl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cilia","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Villanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine Ta Thanh","family":"Minh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina E.","family":"Cazzaniga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2024.103681_bib1","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2024.103681_bib2","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1023\/A:1012539225493","article-title":"A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients","volume":"12","author":"Jassem","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2024.103681_bib3","first-page":"35","article-title":"Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy","volume":"21","author":"Freyer","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103681_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.breast.2019.01.009","article-title":"Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial)","volume":"45","author":"Aapro","year":"2019","journal-title":"Breast"},{"key":"10.1016\/j.breast.2024.103681_bib5","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2024.103681_bib6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","article-title":"The anti-angiogenic basis of metronomic chemotherapy","volume":"4","author":"Kerbel","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.breast.2024.103681_bib7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3816\/CBC.2010.n.039","article-title":"Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer","volume":"10","author":"Addeo","year":"2010","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2024.103681_bib8","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.2147\/OTT.S189163","article-title":"Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?","volume":"12","author":"Cazzaniga","year":"2019","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.breast.2024.103681_bib9","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.3390\/cancers13092236","volume":"13","author":"Cazzaniga","year":"2021","journal-title":"Metronomic chemotherapy. Cancers (Basel)"},{"key":"10.1016\/j.breast.2024.103681_bib10","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd3801","article-title":"The determination and interpretation of the therapeutic index in drug development","volume":"11","author":"Muller","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.breast.2024.103681_bib11","doi-asserted-by":"crossref","first-page":"6454","DOI":"10.1158\/1078-0432.CCR-09-0970","article-title":"Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer","volume":"15","author":"Briasoulis","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2024.103681_bib12","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00280-011-1580-5","article-title":"Phase I trial of metronomic oral vinorelbine in patients with advanced cancer","volume":"68","author":"Rajdev","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.breast.2024.103681_bib13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/1471-2407-13-263","article-title":"Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a Hellenic Cooperative Oncology Group clinical translational study","volume":"13","author":"Briasoulis","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2024.103681_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.breast.2024.103681_bib15","series-title":"Metronomic chemotherapy: pharmacology and clinical applications","first-page":"263","article-title":"Adverse side effects associated with the use of low-dose metronomic chemotherapy","author":"Santos","year":"2014"},{"key":"10.1016\/j.breast.2024.103681_bib16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/0284186X.2020.1851045","article-title":"Metronomic treatment of vinorelbine with oral capecitabine is tolerable in the randomized phase 2 study XeNa including patients with HER2 non-amplified metastatic breast cancer","volume":"60","author":"Brems-Eskildsen","year":"2021","journal-title":"Acta Oncol"},{"key":"10.1016\/j.breast.2024.103681_bib17","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10549-021-06375-5","article-title":"Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study","volume":"190","author":"Cazzaniga","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2024.103681_bib18","doi-asserted-by":"crossref","first-page":"5355","DOI":"10.7150\/jca.60682","article-title":"Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer: a retrospective, observational study","volume":"12","author":"Liu","year":"2021","journal-title":"J Cancer"},{"key":"10.1016\/j.breast.2024.103681_bib19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10549-021-06216-5","article-title":"Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial","volume":"188","author":"Wang","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2024.103681_bib20","doi-asserted-by":"crossref","first-page":"e628","DOI":"10.1097\/CAD.0000000000001209","article-title":"The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients","volume":"33","author":"Montagna","year":"2022","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.breast.2024.103681_bib21","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1007\/s00432-021-03599-2","article-title":"Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced\/metastatic HR+\/HER2- breast cancer resistant to endocrine therapy: VinoMetro-AGO-B-046","volume":"147","author":"Krajnak","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.breast.2024.103681_bib22","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13058-019-1195-z","article-title":"Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial","volume":"21","author":"Adamo","year":"2019","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2024.103681_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100051","article-title":"Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial","volume":"6","author":"Camerini","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2024.103681_bib24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000520236","article-title":"Metronomic chemotherapy for metastatic breast cancer","volume":"45","author":"Krajnak","year":"2021","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.breast.2024.103681_bib25","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.2217\/fon-2019-0124","article-title":"The NAME trial: a direct comparison of classical oral navelbine versus metronomic navelbine in metastatic breast cancer","volume":"15","author":"Langkjer","year":"2019","journal-title":"Future Oncol"},{"issue":"9","key":"10.1016\/j.breast.2024.103681_bib26","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jamaoncol.2023.2150","volume":"9","author":"Munzone","year":"2023","journal-title":"JAMA Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977624000122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977624000122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:47:18Z","timestamp":1760777238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977624000122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":26,"alternative-id":["S0960977624000122"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2024.103681","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive\/HER2-negative advanced breast cancer: The randomized Tempo Breast study","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2024.103681","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103681"}}